The US FDA has granted ODD to ISB 2001 (T-cell engaging trispecific Ab) for the treatment of multiple myeloma
ISB 2001 showed higher potency in vitro compared to daratumumab + teclistamab which is currently under clinical investigation. The results were presented at AACR 2023
ISB 2001 demonstrated enhanced tumor cell death in vitro across variable levels of expression of BCMA and CD38 over teclistamab, alnuctamab, and EM-801. Additionally, the company plans to initiate a P-I first-in-human dose-escalation dose-expansion study of ISB 2001, following approval from the HREC in Australia and IND clearance from the US FDA
Ref: PR Newswire | Image: Ichnos Sciences
Related News:- Innovent and IASO Bio Receive the NMPA’s Approval of Fucaso (equecabtagene autoleucel) for the Treatment of Relapsed or Refractory Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
